CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Terrence C. Kearney has joined its board of directors. The addition of
Mr. Kearney brings the number of Vertex board members to nine. Mr.
Kearney was appointed to the class of directors whose term expires in
2013.
"Mr. Kearney's more than 30 years of financial leadership experience in
the life science industry will be invaluable to our Board as Vertex
advances toward becoming a cash flow and earnings positive company in
2012," said Matthew Emmens, Chairman, President and Chief Executive
Officer of Vertex Pharmaceuticals. "I look forward to Terry's insights
and welcome him to our Board."
Mr. Kearney has more than three decades of global health care experience
at major pharmaceutical and life sciences companies. Most recently, Mr.
Kearney served on the executive management team for Hospira, Inc., where
he held the role of Chief Operating Officer from 2006 through 2010 and
Chief Financial Officer from 2004 to 2006. In these roles, Mr. Kearney
had broad responsibility for the company's global operations, including
commercial, manufacturing and research and development activities, and
financial management strategies. Prior to Hospira, Mr. Kearney spent
more than 20 years at Abbott Laboratories in various financial
management roles, including Vice President and Treasurer. Mr. Kearney
earned a bachelor's degree in biology from the University of Illinois
and a master's in business administration from the University of Denver.
About Vertex
Vertex creates new possibilities in medicine. Our team aims to discover,
develop and commercialize innovative therapies so people with serious
diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to
cure or significantly advance the treatment of hepatitis C, cystic
fibrosis, epilepsy and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, MA, we now have ongoing
worldwide research programs and sites in the U.S., U.K. and Canada.
(VRTX-GEN)
Vertex Pharmaceuticals Incorporated
Investors:
Michael
Partridge, 617-444-6108
or
Lora Pike, 617-444-6755
or
Matthew
Osborne, 617-444-6057
or
Media:
Zachry Barber,
617-444-6470
Source: Vertex Pharmaceuticals Incorporated
News Provided by Acquire Media
